WALTHAM, Mass., May 2, 2025 - Spyre Therapeutics, Inc. $(SYRE)$, a clinical-stage biotechnology company, has announced the approval of stock options as an equity inducement for seven non-executive employees. The company's independent Compensation Committee of the Board of Directors has granted options to purchase a total of 64,400 shares under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. Approved on May 1, 2025, the stock options have a 10-year term with an exercise price of $14.66, matching the closing price of Spyre's common stock on that date. The vesting schedule stipulates that one-fourth of the shares become exercisable on the first anniversary of the employee's start date, with the remainder vesting monthly over four years, contingent on continuous service with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.